The acquisition, pathologic characterization and molecular analysis of human and mouse GI tissue samples is a fundamental and integral for all projects of this SPORE application. The Dana-Farber / Harvard Cancer Center (DF/HCC) SPORE in Gastrointestinal (GI) Cancer Tissue and Pathology Core will continue to provide basic and advance pathology services to SPORE investigators in support the studies outlined in each of the Research Projects, as well as in Career Development and Developmental Projects. The Tissue and Pathology Core will collect, store and provide tissue specimens, through interactions with GI Tumor banks and the DF/HCC Pathology Specimen Locator, perform histologic analyses and provide interpretive pathologic analysis of human esophageal, colonic, pancreatic and GI stromal tumors (GISTs). The Core will ensure that appropriately classified GI cancer tissue samples are used and supplied for all immunohistochemical and molecular analyses proposed. In addition, the Core is committed to the characterization of gastrointestinal neoplasms using advanced molecular pathology tools. A variety of services critical to successful molecular analysis of mouse and human GI tumors will be provided, including;histopathologic review and quality control analysis of all tumor samples utilized in experimental studies;construction of tissue micorarrays to improve and streamline all immunohistochemical analyses;selection and macrodlssection of frozen and formalin-fixed, paraffin-embedded (FFPE) tissue samples to ensure that appropriate cellular compartments are utilized in experimental studies;antibody optimizations for applications in immunohistochemistry (IHC);performance and analysis of a broad range of IHC stains in mouse and human tissues in direct support of the projects;and isolation of nuclei acid extractions from all tissue types (fresh frozen and archival FFPE) for molecular analyses. Finally, the Core will evaluate and implement novel technologies such as ex vivo incubation of GI tumor sections and their subsequent molecular characterization in response to treatment, multiplexing of biomarkers and sophisticated cellular imaging techniques.

Public Health Relevance

The Pathology Core is an essential partner contributing to the success of all projects in the GI SPORE. The presence of a centralized lab supporting each project will avoid redundancy in methodologies, will provide cutting edge molecular pathology methodologies and apply them to GI cancers, and ultimately help guide novel diagnostic and therapeutic discovery.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Russo, Mariangela; Siravegna, Giulia; Blaszkowsky, Lawrence S et al. (2016) Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov 6:147-53
Kugel, Sita; Sebastián, Carlos; Fitamant, Julien et al. (2016) SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell 165:1401-15
Kim, Sun A; Inamura, Kentaro; Yamauchi, Mai et al. (2016) Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. Br J Cancer 114:199-206
Delaney, Susan K; Hultner, Michael L; Jacob, Howard J et al. (2016) Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn 16:521-32
Mima, Kosuke; Cao, Yin; Chan, Andrew T et al. (2016) Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location. Clin Transl Gastroenterol 7:e200
Whitley, Melodi Javid; Cardona, Diana M; Lazarides, Alexander L et al. (2016) A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med 8:320ra4
Ahronian, Leanne G; Corcoran, Ryan B (2016) Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Mol Cell Oncol 3:e1048405
Saha, Supriya K; Zhu, Andrew X; Fuchs, Charles S et al. (2016) Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist 21:594-9
Ou, Wen-Bin; Lu, Minmin; Eilers, Grant et al. (2016) Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53. Br J Cancer 115:1253-1263
Zeng, Chenjie; Matsuda, Koichi; Jia, Wei-Hua et al. (2016) Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk. Gastroenterology 150:1633-45

Showing the most recent 10 out of 481 publications